The concept of “magic bullets” for the treatment of cancerous tumor in a patient, in which a target-specific carrier, such as an antibody specific for a surface antigen on the tumor cells, delivers conjugated toxic molecules to the tumorous cells and kill them, has been well known.
For our new drug molecules designed and developed, they have two moieties, a targeting (T) and an effector (E) moiety.
After such a T-E pharmaceutical is administered to a patient, the targeting moiety directs the drug molecules to specific proteins, cells, or tissues, and the effector moiety mediates its regulatory, cytolytic, or other biological effects.
Compared to the same effector without targeting, the T-E drug can achieve improved efficacy and safety.